Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

November 30, 2012

Conditions
Type 2 Diabetes
Interventions
DRUG

Placebo /Metformin

Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too

DRUG

SP2086(50 mg q.d.)/Metformin

patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks

DRUG

SP2086 (100 mg q.d.)/Metformin

patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks

Trial Locations (1)

Unknown

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01969318 - Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter